Sotrovimab (Xevudy: Vir Biotechnology, GlaxoSmithKline) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

About this update from Vir Biotechnology, Inc.

Key market opportunities for Sotrovimab (Xevudy) include increased prevalence of COVID-19, necessitating early-stage treatment and high-risk patient protection; rising healthcare investments supporting R&D and expanded access; strategic collaborations enhancing development; and expanding regional biologics manufacturing in response to tariffs. Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Sotrovimab or Xevudy Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The report offers invaluable insights for strategists, marketers, and senior management seeking to navigate this rapidly expanding market. A focal point of growth, the sotrovimab or xevudy market is set to shape health and pharmaceutical trends over the next decade. The historic growth of the Sotrovimab (Xevudy) market was driven by the emergency authorization of COVID-19 monoclonal antibodies, a high hospitalization risk during the early pandemic phases, rapid deployment of antibody therapies, and government procurement of antiviral treatments. The expansion of infusion-based treatment infrastructure further supported this growth. Looking ahead, the market is expected to expand due to the evolution of variant-resistant antibody therapies and a growing focus on preparedness for future pandemics. Increased investment in antiviral biologics, the expansion of outpatient infusion services, and the integration of monoclonal antibodies into standard care protocols highlight major trends. This forecast period will see enhanced development of pandemic-response therapeutics and a focus on early-stage viral treatment and high-risk patient protection. With the rising prevalence of COVID-19 cases, the market for Sotrovimab (Xevudy) is likely to experience significant growth. Factors contributing to the continuing increase in cases include the emergence of new variants, waning immunity, relaxed public health measures, and uneven vaccine coverage. Sotrovimab is effective in neutralizing the virus, reducing severe outcomes like hospitalization or death, thus providing critical support for high-risk patients. Rising healthcare investments are expected to propel market growth by advancing research and development efforts, expanding production, and improving access through enhanced distribution networks and partne...

View stock analysis, news, and events for Vir Biotechnology, Inc.